Financial Performance
GSK India reported strong financial results for FY26 with revenue from operations reaching ₹3,821.67 crore (₹3,749.21 crore in FY25) and net profit growing 12% year-on-year to ₹1,035.98 crore. The company achieved profit before exceptional items and tax of ₹1,385.39 crore, demonstrating improved operational efficiency. Key profitability metrics showed strength with operating profit margin at 32.8% and net profit margin at 26.6%.
Dividend and Capital Structure
The Board recommended a final dividend of ₹57 per equity share (subject to shareholder approval at the 101st AGM on June 30, 2026), representing an increase from the previous year's total dividend of ₹54 per share. The company maintains a robust balance sheet with total assets of ₹4,323.87 crore, cash and cash equivalents of ₹1,102.05 crore, and no outstanding bank borrowings. The current ratio improved to 2.0, reflecting strong liquidity management.
Operational Highlights
GSK India maintained its #2 rank among MNCs in the Indian pharmaceutical industry, with leadership positions in private vaccines and dermatology segments. The company successfully launched its oncology business with Jemperli (dostarlimab) and Zejula (niraparib) on August 15, 2025, and introduced locally manufactured Augmentin ES. The Nashik manufacturing facility received BSI AMR Kitemark certification, producing 334 million packs annually.
Digital Transformation and CSR
Digital initiatives showed significant progress with 76% of healthcare professional engagements conducted through digital channels, generating 13.5 million digital touchpoints. The VaxiKart app was used by 12,000+ HCPs, accounting for 45% of pediatric vaccine revenues. Under the 'GSK cares' CSR platform, the company impacted 162,909 beneficiaries and contributed 30 million Albendazole tablets to WHO's lymphatic filariasis elimination program.
Risk Management and Contingencies
The company faces substantial foreign exchange exposure with net liability positions in GBP (₹22.95 crore) and USD (₹55.16 crore), where a 5% currency movement could impact profits by ₹114.74 crore and ₹275.80 crore respectively. Contingent liabilities include ₹247.58 crore in disputed tax matters and ₹265.60 crore in claims not acknowledged as debts. Credit risk management showed ₹17.72 crore in expected credit losses against trade receivables.
Corporate Governance and AGM Details
The 101st Annual General Meeting is scheduled for June 30, 2026, with remote e-voting available from June 26-29, 2026. Key resolutions include approval of commission to non-executive directors for 2026-2031 and ratification of cost auditor remuneration. The company complied with all SEBI LODR requirements and maintained proper corporate governance practices with 6 board meetings and 5 audit committee meetings during the year.
Subsidiary Performance
Wholly-owned subsidiary Biddle Sawyer Limited reported strong performance with revenue of ₹514.51 crore (up from ₹439.95 crore in FY25) and profit after tax of ₹241.61 crore, including an exceptional gain of ₹179.84 crore from sale of investment property. The subsidiary's total assets grew to ₹756.11 crore from ₹358.87 crore in the previous year.